Announcement Regarding Nimodipine Tablets Passing the Generic Drug Consistency Evaluation
October 20, 2026
Source: drugdu
31
Securities Daily News, October 19th - Xinhua PharmaceuticalThe company announced that it recently received the "Approval Notice for Supplemental Application for Drug" for Nimodipine tablets issued by the National Medical Products Administration. The product has passed the consistency evaluation of generic drug quality and efficacy. The specification is 30mg. This product is used as a continuation treatment after prior use of Nimodipine injection, and can prevent and treat ischemic neurological injury caused by cerebral vasospasm following aneurysmal subarachnoid hemorrhage. It belongs to Category A of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2025)".
Source: https://finance.eastmoney.com/a/202610193900147785.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- FDA Approves Revolution Medicines’ Oral RAS Inhibitor Rasonque (daraxonrasib) for Metastatic Pancreatic Cancer October 20, 2026
- Hansoh Pharma Enters Strategic ADC Collaboration with Roche Worth Over US$15.5 Billion October 20, 2026
- New cough medicine launched October 20, 2026
- Shining on the top stage! The world’s first three-target agonist DR10624 MASLD/MASH Phase II results were selected for the latest breakthrough abstract of AASLD. October 20, 2026
- The world’s first long-acting anti-RSV monoclonal antibody has been commercially launched October 20, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
